David A. Siegel Gilead Sciences, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 4,400 shares of GILD stock, worth $477,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,400
Previous 270,796
98.38%
Holding current value
$477,400
Previous $25 Million
98.03%
% of portfolio
0.0%
Previous 0.06%
Shares
30 transactions
Others Institutions Holding GILD
# of Institutions
2,288Shares Held
997MCall Options Held
9.62MPut Options Held
10M-
Black Rock Inc. New York, NY121MShares$13.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$12.7 Billion0.25% of portfolio
-
State Street Corp Boston, MA59.5MShares$6.46 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.6MShares$5.93 Billion1.39% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$5.81 Billion1.01% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $136B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...